During the last two decades treatment based on selective stimulation of immune system has became a promising anti-neoplastic strategy, testing in several clinical centers all over the world. Vac- cination with dendritic cells previously exposed to tumor antigens seems to be one of the most attrac- tive approaches of immunotherapy. Dendritic cell-based vaccines were tested in many early phase clinical trials in patients with solid tumors, including malignant melanoma.

During the last two decades treatment based on selective stimulation of immune system has became a promising anti-neoplastic strategy, testing in several clinical centers all over the world. Vac- cination with dendritic cells previously exposed to tumor antigens seems to be one of the most attrac- tive approaches of immunotherapy. Dendritic cell-based vaccines were tested in many early phase clinical trials in patients with solid tumors, including malignant melanoma.